NEW YORK (dpa-AFX Broker) - U.S. investment bank Goldman Sachs has lowered its price target for Evonik from EUR16.50 to EUR11.60 and downgraded the stock from "Neutral" to "Sell". Analyst Georgina Fraser anticipates continued price pressure on animal feed protein methionine, citing increasing competition and expanded capacities. Fraser outlined these concerns in a generally skeptical sector analysis released Tuesday. She advises investors to keep a close watch on credit markets, which are signaling structural concerns for the chemicals industry. Without significant capacity reductions, a recovery appears unlikely. Fraser has cut her medium-term earnings estimates and, consequently, her price targets by an average of 13 percent./ag/mis
Original report publication: 11.11.2025 / 10:41 / GST
Initial distribution of the original report: Date not specified in the report / Time not specified in the report / Time zone not specified in the report
-----------------------
dpa-AFX Broker - Trader News from dpa-AFX
-----------------------
